Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing Nucleoside Analogs for Human Coronaviruses
Keivan Zandi, Franck Amblard, Katie Musall, et al.
Antimicrobial Agents and Chemotherapy (2020) Vol. 65, Iss. 1
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
Shuntai Zhou, Collin S Hill, Sanjay Sarkar, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 3, pp. 415-419
Open Access | Times Cited: 261
Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase
Keivan Zandi, Katie Musall, Adrian Oo, et al.
Microorganisms (2021) Vol. 9, Iss. 5, pp. 893-893
Open Access | Times Cited: 116
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
Ilaria Vicenti, Maurizio Zazzi, Francesco Saladini
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 4, pp. 325-337
Open Access | Times Cited: 112
Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
Nicola Borbone, Gennaro Piccialli, Giovanni N. Roviello, et al.
Molecules (2021) Vol. 26, Iss. 4, pp. 986-986
Open Access | Times Cited: 70
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19
Arun K. Ghosh, Jennifer L. Mishevich, Andrew D. Mesecar, et al.
ChemMedChem (2022) Vol. 17, Iss. 22
Open Access | Times Cited: 46
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
Thuc Nguyen Dan, Kim Donckers, Laura Vangeel, et al.
Antiviral Research (2021) Vol. 192, pp. 105122-105122
Open Access | Times Cited: 56
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial
Jean‐Jacques Parienti, Thiérry Prazuck, Laure Peyro‐Saint‐Paul, et al.
EClinicalMedicine (2021) Vol. 38, pp. 100993-100993
Open Access | Times Cited: 56
Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuan‐Qin Min, Wei Xiong, Wei Shen, et al.
Science Advances (2024) Vol. 10, Iss. 15
Open Access | Times Cited: 8
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
Isabella Zanella, Daniela Zizioli, Francesco Castelli, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 5, pp. 454-454
Open Access | Times Cited: 39
Drug Repurposing Against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Sarah Aherfi, Bruno Pradines, Christian Devaux, et al.
Future Microbiology (2021) Vol. 16, Iss. 17, pp. 1341-1370
Open Access | Times Cited: 34
Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease
Franck Amblard, Julia C. LeCher, Ramyani De, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116263-116263
Closed Access | Times Cited: 6
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase
Agustina P. Bertolin, Florian Weissmann, Jingkun Zeng, et al.
Biochemical Journal (2021) Vol. 478, Iss. 13, pp. 2425-2443
Open Access | Times Cited: 31
Progress and pitfalls of a year of drug repurposing screens against COVID-19
Julien Sourimant, Megha Aggarwal, Richard K. Plemper
Current Opinion in Virology (2021) Vol. 49, pp. 183-193
Open Access | Times Cited: 28
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2
Kiran Shehzadi, Afsheen Saba, Mingjia Yu, et al.
Topics in Current Chemistry (2023) Vol. 381, Iss. 5
Closed Access | Times Cited: 11
Informatics and Computational Approaches for the Discovery and Optimization of Natural Product-Inspired Inhibitors of the SARS-CoV-2 2′-O-Methyltransferase
George S. Hanna, Menny M. Benjamin, Yeun‐Mun Choo, et al.
Journal of Natural Products (2024) Vol. 87, Iss. 2, pp. 217-227
Open Access | Times Cited: 4
BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir
Wenfang Tang, Yu-Hsiu Chang, Cheng-Chin Lin, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 4
Closed Access | Times Cited: 4
Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
Sijia Tao, Keivan Zandi, Leda Bassit, et al.
Current Research in Pharmacology and Drug Discovery (2021) Vol. 2, pp. 100045-100045
Open Access | Times Cited: 26
Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies
Sarah Mousavi, Shima Zare, Mahmoud Mirzaei, et al.
Canadian Journal of Infectious Diseases and Medical Microbiology (2022) Vol. 2022, pp. 1-70
Open Access | Times Cited: 18
Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures
Winston Chiu, Lore Verschueren, Christel Van den Eynde, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3101-3111
Open Access | Times Cited: 17
Effectiveness of nucleoside analogs against Wetland virus infection
Rui Wang, X. L. Wang, Jianzhong Zhu, et al.
Antiviral Research (2025), pp. 106114-106114
Closed Access
Early Returns on Small Molecule Therapeutics for SARS-CoV-2
Mark Namchuk
ACS Infectious Diseases (2021) Vol. 7, Iss. 6, pp. 1298-1302
Open Access | Times Cited: 21
Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay
Xiaoming Bai, Hongmin Sun, Shuo Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients
José J. García‐Trejo, Raquel Ortega, Mariel Zarco‐Zavala
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 20
Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
Henrik Berg Rasmussen, Ragnar Thomsen, Peter Riis Hansen
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top